Compare iShares MSCI ACWI ETF (ACWI) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Citius Pharmaceuticals Inc — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | CTXR | |
|---|---|---|
52-Week High | $161.44 | $1.82 |
52-Week Low | $132.04 | $0.48 |
Market Cap | — | $20.01M |
Sector | — | Health |
Enterprise Value | — | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.64, up 0.34% today, with a bullish technical signal from moving averages and strong trend momentum indicated by the ADX. The ETF benefits from robust global earnings growth and significant institutional interest, as highlighted by recent news of major holdings. A forward P/E of 15.5x suggests reasonable valuation amid the rally.
The outlook remains positive, driven by sustained EPS growth and investor inflows into global equity ETFs, particularly in technology. Key risks include potential overbought conditions signaled by RSI and broader market volatility. Analyst sentiment is bullish, supporting further upside potential.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
